Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 7,040 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $52.76, for a total value of $371,430.40. Following the completion of the sale, the chief executive officer directly owned 74,760 shares of the company’s stock, valued at $3,944,337.60. The trade was a 8.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $55.91, for a total value of $393,606.40.
• On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $54.29, for a total value of $382,201.60.
• On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $54.64, for a total value of $384,665.60.
• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $59.08, for a total value of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total value of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total value of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total value of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total value of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total value of $361,644.80.

Phibro Animal Health Stock Performance

PAHC traded up $0.68 on Thursday, reaching $53.18. 295,999 shares of the stock were exchanged, compared to its average volume of 241,713. The company’s 50-day moving average price is $53.86 and its 200 day moving average price is $46.10. Phibro Animal Health Corporation has a fifty-two week low of $18.33 and a fifty-two week high of $60.08. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The firm has a market capitalization of $2.16 billion, a PE ratio of 23.64, a PEG ratio of 0.81 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, sell-side analysts forecast that Phibro Animal Health Corporation will post 3.03 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Wednesday, March 4th. Phibro Animal Health’s payout ratio is 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. 1620 Investment Advisors Inc. increased its stake in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares in the last quarter. Hughes Financial Services LLC purchased a new position in shares of Phibro Animal Health in the 3rd quarter valued at about $40,000. Rothschild Investment LLC increased its stake in shares of Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Phibro Animal Health in the 3rd quarter valued at about $61,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. Citigroup assumed coverage on Phibro Animal Health in a report on Wednesday, April 15th. They issued a “neutral” rating and a $62.00 price objective for the company. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $42.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.